Company intelligence / Profile preview

Benovus Bio, Inc.

Atlanta, Georgia, United States

Ownership: Private
Employees: ~2
Development stage: Preclinical

Overview

Benovus Bio has developed high-affinity antibodies targeting the C-terminal region of OFA/iLRP for potential therapeutic and diagnostic use in oncology. The company also appears as a player in the synthetic peptide vaccine space targeting various cancers. No published late-stage clinical results were found.

Therapeutic areas: Oncology
Modalities: Monoclonal antibodies (mAbs)synthetic peptide vaccines
Industry: Biotech

Drug pipeline

1 asset

BB-MPI-03

Partnerships

South Alabama Medical Science Foundation (patent co-applicant)

Beyond the preview

Go deeper on Benovus Bio, Inc..

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Benovus Bio, Inc..

Explore the full profile